White Linda R, Gårseth Mari, Aasly Jan, Sonnewald Ursula
Department of Neuroscience, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
J Neurosci Res. 2004 Oct 15;78(2):297-301. doi: 10.1002/jnr.20241.
Increased levels of an unidentified peak have been found in cerebrospinal fluid (CSF) from patients with Alzheimer's disease or vascular dementia compared to the level in healthy controls using proton magnetic resonance spectroscopy. No increase was found in patients with amyotrophic lateral sclerosis. Reexamination of spectra from a study published previously (Gårseth et al. [2000] J. Neurosci. Res. 60:779-782), however, shows that this peak was also elevated significantly in CSF from patients with Huntington's disease compared to that in controls. The level in patients with Parkinson's disease, where dementia develops in up to 40% of patients, was not elevated significantly compared to that in controls. To the best of our knowledge, this peak has not yet been identified and we therefore find it appropriate to temporarily designate the name "dementia associated factor" (DAF), although there is as yet no certainty that this substance is specific for these conditions. Apart from a significantly increased level of glutamine in CSF from patients with vascular dementia compared to that in controls, no other significant difference was found for any other metabolite measured in the patient groups using proton magnetic resonance spectroscopy.
与健康对照相比,使用质子磁共振波谱法发现,阿尔茨海默病或血管性痴呆患者脑脊液(CSF)中一个未鉴定峰的水平升高。肌萎缩侧索硬化症患者未发现升高。然而,对先前发表的一项研究(Gårseth等人,[2000]《神经科学研究杂志》60:779 - 782)的光谱重新检查显示,与对照相比,亨廷顿病患者脑脊液中的这个峰也显著升高。帕金森病患者中高达40%会出现痴呆,与对照相比,其水平未显著升高。据我们所知,这个峰尚未被鉴定,因此我们认为暂时命名为“痴呆相关因子”(DAF)是合适的,尽管目前还不能确定这种物质对这些病症具有特异性。与对照相比,血管性痴呆患者脑脊液中谷氨酰胺水平显著升高,使用质子磁共振波谱法在患者组中测量的任何其他代谢物均未发现其他显著差异。